Table 3.
Safety Profile of the 83 Elderly Patients with Advanced NSCLC Receiving Anlotinib Monotherapy
| Adverse Reactions | Total (N, %) | Grade 1–2 (N, %) | Grade ≥3 (N, %) |
|---|---|---|---|
| Hypertension | 41 (49.4) | 26 (31.3) | 15 (18.1) |
| Fatigue | 38 (45.8) | 33 (39.8) | 5 (6.0) |
| Hand-foot syndrome | 33 (39.8) | 27 (32.5) | 6 (7.2) |
| Diarrhea | 28 (33.7) | 25 (30.1) | 3 (3.6) |
| Loss of weight | 26 (31.3) | 22 (26.5) | 4 (4.8) |
| Decreased appetite | 18 (21.7) | 17 (20.5) | 1 (1.2) |
| Hematological toxicity | 15 (18.1) | 13 (15.7) | 2 (2.4) |
| Hypertriglyceridemia | 11 (13.3) | 10 (12.1) | 1 (1.2) |
| AST/ALT elevation | 8 (9.6) | 7 (8.4) | 1 (1.2) |
| Hemoptysis | 5 (6.0) | 4 (4.8) | 1 (1.2) |
Abbreviations: NSCLC, non-small cell lung cancer; AST, aspartate amino transferase; ALT, alanine aminotransferase.